Stocks and Investing Stocks and Investing
Thu, May 4, 2023
Wed, May 3, 2023

Gil Blum Reiterated (SRPT) at Strong Buy and Held Target at $160 on, May 3rd, 2023


Published on 2024-10-28 03:20:13 - WOPRAI, Gil Blum
  Print publication without navigation


Gil Blum of Needham, Reiterated "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy and Held Target at $160 on, May 3rd, 2023.

Gil has made no other calls on SRPT in the last 4 months.



There are 12 other peers that have a rating on SRPT. Out of the 12 peers that are also analyzing SRPT, 0 agree with Gil's Rating of Hold.



These are the ratings of the 12 analyists that currently disagree with Gil


  • David Hoang of "SMBC Nikko" Initiated at Buy and Held Target at $185 on, Wednesday, April 26th, 2023
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $164 on, Friday, April 14th, 2023
  • Uy Ear of "Mizuho" Reiterated at Strong Buy and Held Target at $160 on, Friday, April 14th, 2023
  • Gavin Clark-Gartner of "Evercore ISI Group" Maintained at Buy and Held Target at $149 on, Thursday, April 13th, 2023
  • Neena Bitritto-Garg of "Citigroup" Initiated at Strong Buy and Held Target at $179 on, Tuesday, April 4th, 2023
  • Ritu Baral of "TD Cowen" Maintained at Buy with Increased Target to $175 on, Wednesday, March 22nd, 2023
  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Decreased Target to $150 on, Thursday, March 9th, 2023
  • Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $206 on, Friday, March 3rd, 2023
  • Brian Skorney of "Baird" Maintained at Buy with Increased Target to $202 on, Wednesday, March 1st, 2023
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $190 on, Wednesday, March 1st, 2023
  • Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy and Increased Target to $187 on, Wednesday, March 1st, 2023
  • Joseph Schwartz of "SVB Leerink" Reiterated at Buy and Held Target at $160 on, Friday, January 20th, 2023
Contributing Sources